Gastroenterology

Achieving PFS in Advanced Gastric Cancer With HLX02 Biosimilar, Chemotherapy

November 23rd 2024

By Deana Ferreri, PhD

In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in untreated HER2-positive advanced gastric cancer patients.

Subcutaneous Infliximab CT-P13 Superior to Placebo as Maintenance Therapy for IBD

November 16th 2024

By Deana Ferreri, PhD

In 2 randomized controlled trials of maintenance therapy for inflammatory bowel disease (IBD), the subcutaneous formulation of the infliximab biosimilar CT-P13 demonstrated superiority to placebo in patients with Crohn disease and ulcerative colitis.

Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD

November 9th 2024

By Deana Ferreri, PhD

A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.

Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo

November 7th 2024

By Skylar Jeremias

For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.

Celltrion Sets Sights on 2030 With Expanded Biosimilar Portfolio, Market Reach

November 6th 2024

By Skylar Jeremias

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by core biosimilars and new launches like subcutaneous infliximab.

Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data

November 5th 2024

By Skylar Jeremias

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.

Making the Cost of IBD Care Sustainable

November 2nd 2024

By Deana Ferreri, PhD

How Policy Reforms in PBM Systems Could Change the Adalimumab Market

October 28th 2024

By Skylar Jeremias

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve accessibility, affordability, and fair competition for adalimumab biosimilars.

Veterans’ Experience With Infliximab Biosimilars for IBD Treatment

October 26th 2024

By Deana Ferreri, PhD

A study of the Veterans Health Administration detailed their experience with infliximab biosimilars in a population of patients with inflammatory bowel disease (IBD) who were naive to infliximab.

Addressing Hesitance in Biosimilar Adoption

October 20th 2024

By Skylar Jeremias

Sophia Humphreys, PharmD, from Sutter Health explains that expanding biosimilars into new therapeutic areas faces hesitance due to maintenance therapies, emphasizing the importance of education.